According to PRNewswire , Edwards Lifesciences Corporation recently completed its acquisition of CardiAQ Valve Technologies, Inc , a developer of transcatheter mitral valve replacement systems, which follows from Edwards' acquisition agreement announced last month. The article reports that Edwards paid $350 million cash for CardiAQ at closing, with an additional $50 million to be paid upon reaching a European regulatory milestone.